Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIROC-1: Misetionamide in Advanced Solid Tumors
NCT03854110Phase 1Recruiting
- Sponsor
- Persevere Therapeutics
- Start
- Jan 2019
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of misetionamide in ovarian cancer and pancreatic cancer (PC), sponsored by Persevere Therapeutics. Primary endpoint: Safety, tolerance and recommended misetionamide dose for subsequent studies in PROC. Started Jan 2019; status: recruiting.
02
Drugs
misetionamide
03
Conditions
ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03854110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854110.